Zimmer Biomet Holdings Inc

Sales Growth: Zimmer Biomet reported a 2.3% constant currency growth in sales for Q1 2025, reaching $1.909 billion. U.S. Hip sales increased nearly 4%, and S.E.T. saw mid-single-digit growth. However, the results were against a backdrop of one less selling day compared to the previous year, indicating potential higher growth without this headwind.

2025 Full Year Guidance: The company maintains its organic constant currency revenue growth expectations for 2025 at 3% to 5%, excluding contributions from the recent Paragon 28 acquisition, which is expected to contribute an additional 270 basis points to sales growth.

Diluted EPS Update: Adjusted earnings per share (EPS) guidance for 2025 has been revised downward to a range of $7.90 to $8.10 from the previous projection of $8.15 to $8.35, primarily due to tariff impacts, shifts in discretionary spending, and operational strategies. This indicates a cautious outlook reflecting challenges in maintaining margins amidst external pressures.